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Background: Artemisia capillaries Thunb. (AC) has been used to treat inflammatory and hepatic disorders such as
hepatic injury, hepatic fibrosis and hepatitis. However, the efficacy of AC against atopic dermatitis (AD), an
inflammatory disease, has not been examined. In the present study, AC was evaluated for anti-inflammatory and
anti-AD effects using both in vitro and in vivo systems.
Methods: The contents of six compounds (chlorogenic acid, caffeic acid, isochlorogenic acid A, hyperoside,
isoquercitrin and scoparone) in AC were simultaneously assayed using HPLC system. To evaluate the anti-inflammatory
effect of AC, NO production was measured in RAW264.7 cell stimulated with 1 μg/mL LPS. Histamine levels
were assayed in MC/9 cells stimulated with 50 nM PMA and 1 μM A23187. To examine the role of AC in vivo,
AC (10 mg/mouse/day) was topically applied for four weeks the back and ears of Dermatophagoides farinae-sensitized
Nc/Nga mice. Protopic ointment (0.1% tacrolimus) was used as a positive control.
Results: The contents of the six components in AC range from 0.44 to 43.14 mg/g. Chlorogenic acid (21.06 ± 0.08 mg/g)
and isochlorogenic acid A (43.14 ± 0.12 mg/g) were major components in AC. AC inhibited NO and histamine
production in cells respectively. In D. farinae-sensitized Nc/Nga mice, the topical application of AC reduced dermatitis
scores, hemorrhage, hypertrophy and hyperkeratosis of the epidermis in the dorsal skin and ear. The treatment of AC
also reduced the plasma levels of histamine (1.5 fold) and IgE (1.4 fold).
Conclusions: Our results suggest that AC should be explored as a potential therapeutic agent to treat atopic
dermatitis and analysis by HPLC will help to improve the quality of AC.
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Atopic dermatitis (AD) is an inflammatory, chronically
relapsing, non-contagious and pruritic skin disorder [1].
AD is often accompanied by allergic inflammation, which
is initiated by activation of the adaptive immune response.
Immunoglobulin E (IgE) is produced in plasma cells and
bound by mast cells in type I allergic reactions. The IgE-
primed mast cells release chemical mediators, such as
histamine, leukotrienes (LTs) and prostaglandin D2* Correspondence: hkshin@kiom.re.kr
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reproduction in any medium, provided the or(PGD2). These mediators lead to immediate phase reac-
tions in the tissue, such as redness and itching, shortly
after allergen-IgE binding. In the later phases of the dis-
ease, cytokines (IL-4 and IL-13) and chemokines are
generated and released several hours after allergen-
antibody cross-linking [2].
Topical corticosteroids are currently the most potent
treatment for AD. However, patients with more severe
forms of the disease do not always respond satisfactorily
to these agents. Chronic use can also be associated with
significant adverse effects. The long-term use of cortico-
steroids results in tachyphylaxis and treatment resistance.
Therefore, it would be advantageous to develop new treat-
ments that lack the side effects of corticosteroids [3]. TheThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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the short-term treatment of AD. However, no studies exist
to support their long-term use, and both rebound flaring
and long-term side effects are limiting factors [4]. Im-
munosuppressive drugs, including calcineurin inhibitors
such as cyclosporine, tacrolimus and pimecrolimus, have
been reported to be effective for atopic dermatitis. How-
ever, concerns over systemic toxicity have limited their
use [5,6]. Tacrolimus has been developed for the treat-
ment of moderate to severe AD, but topical tacrolimus
ointment causes transient burning in ~60% of patients [6].
Consequently, the need to efficiently manage the AD re-
sponse while reducing side effects has led to the develop-
ment of alternative remedies.
Artemisia capillaris Thunb. (AC) has been tradition-
ally used as an herbal medicine to treat pyrexia and liver
disorders in East Asia. Several studies have also estab-
lished that AC inhibits chemical-induced oxidative
stress, hepatic injury, hepatic fibrosis, hepatitis and obes-
ity [7-10]. Additionally, Kim et al. [11] reported that AC
extracted with boiling water inhibits cytokine-induced
nitric oxide (NO) formation in a rat insulinoma cell line.
However, the efficacy of AC in treating AD has not been
examined.
In the present study, we evaluated the anti-inflammatory
and anti-allergic effects of AC by measuring its inhibition
of NO production in lipopolysaccharide (LPS)-treated
RAW264.7 cells. Furthermore, we analyzed histamine
production in MC/9 cells stimulated with phorbol-12
myristate 13-acetate (PMA) and A23187, in addition to
analyzing the AD response in Nc/Nga mice.
Methods
Plant materials and extract
A. capillaris was purchased from Kwangmyungdang Me-
dicinal herbs (Ulsan, Korea) in September 2009. These
materials were confirmed taxonomically by Professor Je-
Hyun Lee of Dongguk University, Korea. A voucher spe-
cimen (AC-2009-EBM30) has been deposited at the
Herbal Medicine Formulation Research Group at the
Korea Institute of Oriental Medicine.
The 300 g sample of dried A. capillaris was extracted
with 70% EtOH (3 L × 3) by sonication for 60 min. The
extract solution was filtered through Whatman No. 2 fil-
ter paper (150 mm diameter, Buckinghamshire, UK) and
evaporated to dryness using a rotary evaporator. The
yield of 70% EtOH extract was 8.30% (24.89 g).
Chemicals and reagents
Chlorogenic acid and caffeic acid were purchased from
Acros Organics (Pittsburgh, PA, USA). Hyperoside and
scoparone were purchased from Sigma-Aldrich (St.
Louis, MO, USA). Isoquercitrin and isochlorogenic acid
A were purchased from Biopurify Phytochemicals Ltd.(Chengdu, China). The purity of the six compounds was
determined to be ≥97% by HPLC analysis. HPLC-grade
reagents, methanol, acetonitrile, and water were ob-
tained from J.T.Baker (Phillipsburg, NJ, USA). Glacial
acetic acid was of analytical reagent grade and was pro-
cured from Junsei (Tokyo, Japan).
Chromatographic conditions of HPLC analysis
The HPLC analysis was performed using a Shimadzu
LC-20A HPLC system (Shimadzu Co., Kyoto, Japan)
consisting of a solvent delivery unit, an on-line degasser,
a column oven, an autosampler and a PDA detector.
The data processor used LC Solution software (version
1.24, Shimadzu Co., Kyoto, Japan). The analytical col-
umn used was a Gemini C18 (250 × 4.6 mm; particle size
5 μm; Phenomenex, Torrance, CA, USA) maintained at
40°C. The mobile phases were composed of 1.0% (v/v)
aqueous acetic acid (A) and 1.0% (v/v) acetic acid in
acetonitrile (B). The gradient flow rate was as follows:
0–5 min, 0–10% B; 5–30 min, 10–50% B; 30–35 min,
50–50% B; 35–40 min, 50–10% B. The flow rate and in-
jection volume were 1.0 mL/min and 10 μL, respectively.
The detection wavelength was set at 254 nm for hypero-
side and isoquercitrin, at 320 nm for chlorogenic acid,
caffeic acid, and isochlorogenic acid A and at 340 nm
for scoparone.
Preparations of standard and sample solutions
Standard stock solutions of three phenolic acids (chloro-
genic acid, caffeic acid and isochlorogenic acid A), two fla-
vonoids (hyperoside and isoquercitrin) and one coumarin
(scoparone) (Figure 1A) were dissolved in methanol at con-
centrations of 1.0 mg/mL and kept at 4°C. The working
standard solutions were diluted to calibration curves in the
concentration range of 0.78–50.00 μg/mL for chlorogenic
acid, hyperoside and scoparone, 0.16–10.00 μg/mL for caf-
feic acid and isoquercitrin and 2.34–150.00 μg/mL for iso-
chlorogenic acid A.
The 70% EtOH extract (20 mg) was dissolved in 70%
EtOH (10 mL) and then filtered through a 0.2 μm mem-
brane filter (Woongki Science, Seoul, Korea) before in-
jection into the HPLC for simultaneous analysis.
Measurement of nitric oxide (NO) production in
LPS-treated RAW264.7 cells
RAW 264.7 murine macrophage cells were obtained from
the American Type Culture Collection (ATCC, Rockville,
MD, U.S.A.) and maintained in Dulbecco’s modified
Eagle’s medium (DMEM, Gibco BRL., NY, U.S.A.) sup-
plemented with 5.5% (v/v) fetal bovine serum (FBS, Gibco
BRL., NY, U.S.A.), 100 U/mL penicillin and 100 μg/mL
streptomycin (Gibco BRL, NY, U.S.A.). The cells were
seeded at densities of 2.5×103 cells/well in 96-well plates
for the cytotoxicity assay. The cells were then incubated
Figure 1 Chemical structures and HPLC chromatograms. A: Chemical structures of six marker components of A. capillaris. B: Representative HPLC
chromatogram of reference standards. C: Representative HPLC chromatogram of A. capillaris extract. The detection wavelength was set at 254 nm (I) for
hyperoside (3) and isoquercitrin (4), at 320 nm (II) for chlorogenic acid (1), caffeic acid (2), and isochlorogenic acid A (5) and at 340 nm (III) for scoparone (6).
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and 100 μg/mL) for 24 hr. The vehicle control was 1%
DMSO. After treatment, 10 μL of Cell Counting Kit-8 re-
agent (CCK-8, Dojindo, Japan) was added to each well and
the plates were incubated for 4 hr. The absorbance was
measured at 450 nm using a microplate reader (Bench-
markPlus, Bio-Rad Laboratories Inc., U.S.A.) and the per-
centages of viable cells were calculated. AC extracts in the
range of 20–200 μg/mL did not cause cytotoxicity in
RAW 264.7 cells and non-cytotoxic concentrations of
herbal extracts were used for the subsequent experiments.
RAW 264.7 cells were seeded at a density of 5×105
cells in a 48-well plate for the NO assay. After culturing
for 16 hr, the cells were stimulated with 1 μg/ml of LPS in
the presence or absence of AC extracts (20–200 μg/mL)
for 18 hr. NG-methyl-L-arginine (NMMA; Sigma-Aldrich,
Inc., MO, U.S.A.) and indomethacin (Sigma-Aldrich, Inc.,
MO, U.S.A.) were used as positive controls. A Griess re-
agent system (Promega., WI, U.S.A.) was used to measure
the production of NO in the culture supernatants. Briefly,
samples (50 μL/well) were incubated at room temperature
with 1% sulfanilamide for 10 min and with 1% α-
naphthylamine for 10 min. The absorbance was then
evaluated at 535 nm using a calibration curve generated
using the standards.
Measurement of histamine in PMA/A23187-treated
MC/9 cells
The murine mast cell line MC/9 was maintained in
DMEM media containing 10% (v/v) FBS, 0.05 mM 2-
mercaptoethanol (Sigma Chemical Co., MO, U.S.A.), 10%
(v/v) Rat T-STIM (BD Biosciences, MA, U.S.A.), 100 U/mL
of penicillin and 100 μg/mL of streptomycin in a humidi-
fied 5% CO2 atmosphere. The MC/9 cells were plated in
48-well plates at a concentration of 2×105 cells per well.
The cells were either untreated or treated with either phor-
bol 12-myristate 13-acetate (50 nM; PMA, Sigma-Aldrich,
Inc., MO, U.S.A.) and A23187 (1 μM; Sigma-Aldrich,
Inc., MO, U.S.A.) alone or PMA/A23187 (PA) + AC
(50–200 μg/mL) for 24 hr. The histamine levels in the
MC/9 cell supernatants were measured by ELISA in ac-
cordance with the manufacturer’s instructions (Oxford
Biomedical Research, U.S.A.).
Animals and sensitization
Male Nc/Nga mice (8 weeks old) were obtained from
Central Laboratory Animal Inc. (Seoul, Korea) and
housed individually in an air-conditioned room main-
tained at 24 ± 2°C with 55 ± 15% relative humidity. The
animals were allowed to acclimatize for 2 weeks before
the experiments were initiated. All experimental proce-
dures were carried out in accordance with the NIH
Guidelines for the Care and Use of Laboratory Animals
and were approved by Korea Institute of Oriental MedicineInstitutional Animal Care and Use Committee. The ap-
proval number for the animal study was #10-052. The ani-
mals were cared for in accordance with the dictates of the
National Animal Welfare Law of Korea.
AD-like skin lesions were induced in male Nc/Nga
mice using Dermatophagoides farinae extract ointment
(Biostir-AD, Biostir Co., Ltd., Kobe, Japan) [12]. At ten
weeks of age the mice were grouped randomly into four
groups with seven mice per group. The mice were divided
into untreated (normal; 200 μL of 70% EtOH/mouse/day),
D. farinae-sensitized (control; 70% EtOH), D. farinae-sen-
sitized plus Protopic® ointment-treated (Protopic; 50 mg/
mouse/day) and D. farinae-sensitized plus AC extract-
treated (AC; 10 mg/mouse/day) groups. For sensitization,
50 mg Biostir-AD was topically applied on the upper dor-
sal skin and the back of the ears twice weekly for 4 weeks.
The AC extract was dissolved 70% ethanol and applied
every day for 4 weeks.
Dermatitis score
The dermatitis scores were assessed by evaluating the
dorsal skin and the ears once a week for 4 weeks. The
Eczema Area and Severity Index (EASI) scoring system
was employed to evaluate the severity of dermatitis. The
dermatitis score was defined as the sum of the scores for
erythema/hemorrhage, edema, excoriation/erosion and
scaling/dryness and scored as follows: no symptoms, 0;
mild, 1; moderate, 2; and severe, 3 [4].
Histological analysis
Mice were anesthetized by pentobarbital sodium (Entobar
inj., Hanlim Pharm. Co., Ltd., Korea) injection (i.p.). Blood
samples were taken and the animals were sacrificed by ex-
sanguination from the aorta. A complete gross observa-
tion was performed on all terminated animals. The blood
samples were collected in a microtainer (Becton, Dickinson
and Company, NJ, USA) containing K2-EDTA. Plasma
samples were collected after centrifugation at 10000 rpm
and stored at −80°C until they were further assayed. The
dorsal skin and one ear of each mouse were removed and
fixed in 10% (v/v) natural buffered formalin for 24 hr. The
tissues were embedded in paraffin and then sectioned at
4 μm thickness. The tissue sections were then stained with
hematoxylin & eosin (H&E) or toluidine blue to estimate
epidermal inflammation (hypertrophy and infiltration by in-
flammatory cells) and mast cell counts, respectively. The
dermal mast cell content was quantified by counting the
numbers of toluidine-blue positive cells in randomly se-
lected high power fields for each specimen.
Plasma levels of IgE and histamine
The plasma levels of IgE (Bethyl Laboratories Inc., U.S.A.)
and histamine (Oxford Biomedical Research, U.S.A.)
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Statistical analysis
The data are expressed as the mean ± SEM and were ana-
lyzed using a one-way ANOVA followed by the Bonferroni
multiple comparison test. A P-value <0.05 was defined as
statistically significant. All statistical analyses were per-




The HPLC-PDA method was utilized for simultaneous
determination of the chlorogenic acid, caffeic acid,
hyperoside, isoquercitrin, isochlorogenic acid A and sco-
parone content of A. capillaris using mobile phases
comprised of 1.0% (v/v) acetic acid in water (A) and
1.0% (v/v) acetic acid in acetonitrile (B). Using optimized
chromatography conditions, the six compounds were
eluted within 30 min in the sample analysis. The correl-
ation coefficients (r2) of the calibration curves for six
components were ≥ 0.9999. The ranges of LOD and
LOQ were 38.40–126.49 ng/mL and 128.00–421.62 ng/
mL, respectively. The linear equations and the r2 of the
calibration curves are summarized in Table 1. The re-
producibility for all analytes showed an RSD of less than
1.0% for peak responses and less than 0.2% for retention
times (data not shown). The retention times of chloro-
genic acid, caffeic acid, hyperoside, isoquercitrin, iso-
chlorogenic acid A, and scoparone were 11.63, 14.80,
19.53, 19.78, 21.63, and 23.66, respectively. The HPLC
chromatograms of the standard solution and water ex-
tract of A. capillaries are shown in Figure 1B and C. The
contents of the six constituents ranged from 0.44–
43.14 mg/g. Chlorogenic acid and isochlorogenic acid A
were the major components in A. capillaris extract
(Table 2).
Inhibitory effects of AC on NO and histamine production
AC was shown to inhibit the inflammatory response in
LPS-stimulated RAW264.7 cells. LPS-induced NO pro-
duction was significantly reduced by AC extract in aTable 1 Calibration curves for the six marker components of
Component Linear range (μg/mL) Regression
Chlorogenic acid 0.78–50.00 Y = 32627.70x
Caffeic acid 0.16–10.00 Y = 60172.54x
Hyperoside 0.78–50.00 Y = 25100.81x
Isoquercitrin 0.16–10.00 Y = 26489.61
Isochlorogenic acid A 2.34–150.00 Y = 38075.16x
Scoparone 0.78–50.00 Y = 37297.38x
aY represents peak area (mAU); x represents concentration (μg/mL).dose-dependent manner compared to the group treated
with LPS alone (P < 0.01, IC50 = 87.82 μg/mL, Figure 2A).
The PA-stimulated MC/9 cells treated with AC showed
a decline in histamine production compared with that of
cells stimulated with PA alone (P < 0.01, Figure 2B).Dermatitis scores and histological observations in
Nc/Nga mice
Representative photographs for each group of animals
are shown in Figure 3A. Macroscopically, the mice de-
veloped lesions on the dorsal skin and ears starting at
the second week after the initiation of D. farinae extract
treatment. In the AC-treated group, the dorsal skin and
ear lesion severity was significantly reduced compared to
the control group at the third week (P < 0.01). However,
the dermatitis score of Protopic-treated positive control
group was no different than that of the control group
(Figure 3B). The maximum dermatitis score was recorded
following the fourth week of D. farinae extract application
in all groups. The scores for each group were as follows:
0.0 ± 0.00 (normal), 7.1 ± 0.43 (control), 8.1 ± 0.54 (Protopic)
and 5.9 ± 0.49 (AC) (Figure 3B).
The control and Protopic treatment groups showed sig-
nificant inflammatory changes, including ear lesions and
hemorrhage, hypertrophy, and hyperkeratosis of the epi-
dermis in the dorsal. These changes were significantly
ameliorated in the AC treatment group. The infiltration of
mast cells in the dorsal skin was reduced by the applica-
tion of AC to AD-induced mice (Figure 3C).Plasma levels of histamine and IgE
The plasma histamine levels in the control group (39.85 ±
5.44 ng/mL) were elevated compared to the normal group
(28.56 ± 2.56 ng/mL). The histamine levels were reduced
in the AC and Protopic treatment groups (25.12 ±
2.94 ng/mL and 25.54 ± 1.93 ng/mL, respectively) com-
pared to the control group (P < 0.05, Figure 4A). Addition-
ally, the total plasma IgE levels were significantly increased
in the control group (211.3 ± 13.35 ng/mL) compared to
the normal group (41.56 ± 7.022 ng/mL, P < 0.01). The
treatment with AC inhibited increases in plasma IgE
levels (149.9 ± 22.66 ng/mL) in D. farinae-sensitizedA. capillaris (n = 3)
equationa r2 LOD (ng/mL) LOQ (ng/mL)
– 4523.06 1.0000 126.49 421.62
– 1297.07 0.9999 43.64 145.45
+ 2699.33 0.9999 39.56 132.88
x + 23.88 1.0000 38.40 128.00
– 21283.50 0.9999 51.62 172.06
+ 3577.02 0.9999 51.24 170.79
Table 2 Contents of the six marker compounds in the
70% ethanol extract of A. capillaris (n = 3)
Compound Content (mg/g)
Mean SD RSD (%)
Chlorogenic acid 21.06 0.08 0.36
Caffeic acid 0.44 0.01 1.54
Hyperoside 8.44 0.03 0.38
Isoquercitrin 2.96 0.01 0.21
Isochlorogenic acid A 43.14 0.12 0.27
Scoparone 5.56 0.02 0.43
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in the Protopic group (175.4 ± 20.36 ng/mL, Figure 4B).
Discussion
AD is a common chronic cutaneous disease characterized
by the over-expression of IL-10 and by high IgE levels.
The most important allergens associated with human ADFigure 2 Inhibitory effects of NO and histamine production by A. cap
(1 μg/mL, 24 hr) RAW 264.7 cells in a concentration-dependent manner (m
**: P < 0.01 compared with the LPS-treated group). B: Histamine production
1 μM, 24 hr) MC/9 cells (mean ± SEM (n = 3), ##: P < 0.01 compared with theare house dust mite allergens, and D. farinae is the most
common house dust mite present in the environment.
The development of inflammation in AD is biphasic. An
initial Th2 phase leads to a chronic phase associated with
Th0 and Th1 cells [1]. The drugs currently used to treat
AD are limited by the significant adverse effects associated
with their long-term use. Recently, several studies have
attempted to identify new candidates to treat AD with
fewer side effects. Herbal remedies, including herbal medi-
cines, are a popular trend in the field of complementary
and alternative medicine. In previous reports, an extract
of A. capillaris was shown to inhibit 5-lipoxigenase
(5-LOX) activity in the RBL-1 cell line. The activity of
5-LOX is associated with several allergic and skin in-
flammatory disorders [11].
In the present study, the chemical contents of the AC ex-
tract were analyzed using a high performance liquid chro-
matography (HPLC) system. Kwon et al. reported that the
major compounds of A. capillaris are scopoletin, scopolin,
scoparone, esculetin, quercetin, capillarisin, isorhamnetin,illaris extract (AC). A: AC inhibited NO production in LPS-stimulated
ean ± SEM (n = 3), ##: P < 0.01 compared with the control group,
was reduced by AC in PMA and A23187 (PA)-treated (50 nM and
control group, **: P < 0.01 compared with the PA-treated group).
Figure 3 (See legend on next page.)
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Figure 3 Dermatitis scores and histological changes in D. farinae extract-sensitized Nc/Nga mice. A: Macroscopic changes following
consecutive administration of A. capillaris extract (AC) or Protopic ointment to D. farinae-induced AD like lesions on the back and ears in Nc/Nga
mice. The images show the back and ears 4 weeks after sensitization. B: The dermatitis scores of D. farinae-induced AD-like lesions on the back
and ears (mean ± SEM (n = 5), *: P < 0.05 and **: P < 0.01, compared with the normal group, ##: P < 0.01, compared with the D. farinae-induced
control group). AC (10 mg/mouse/day) and Protopic ointment (50 mg/mouse/day) were topically applied on the back and ears once daily for
4 weeks. C: Histological features of the back and ears. The tissues were stained with hematoxylin & eosin (H&E) or toluidine blue to estimate
epidermal inflammation or mast cell infiltration. The mast cells are indicated by arrows.
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chlorogenic acid [10]. However, Artemisia species are
very varied such as A. capillaris, A. princeps, A. iwayo-
mogi, A. ontana, A judaica, etc. Moreover, it has been
reported various compounds including coumarins (scopar-
one, scopoletin, scopolin, etc.), flavonoids (isorhamnetin,
quercetin, isoquercitrin, hyperoside, etc.), chromones (capil-
larisin, 7-methylcapillarisin, etc.), phenylpropanoids (caffeic
acid, chlorogenic acid, caffeoylquinic acids, etc.), lignansFigure 4 The plasma levels of histamine (A) and IgE (B) in D. farinae e
ointment (50 mg/mouse/day) were topically applied on the back and ears
measured by ELISA (mean ± SEM, n = 5), ##: P < 0.01 compared with the no
group.((+)-sesamin, pluviatide, honokiol, etc.), and essential oils
(β-pinene, β-caryophyllene, capillene, etc.) [13-19]. Among
these different constituents, we were selected the six com-
pounds including caffeic acid, chlorogenic acid, hypero-
side, isoquercitrin, isochlorogenic acid A, and scoparone.
Six compounds were selected as the marker compounds
of A. capillaris in this study with references [13-15], and
then performed simultaneous analysis using HPLC-PDA
method. Isochlorogenic acid A and chlorogenic acid werextract-sensitized Nc/Nga mice. AC (10 mg/mouse/day) and Protopic
once daily for 4 weeks. The concentrations of histamine and IgE were
rmal group, *: P < 0.05 compared with the D. farinae-induced control
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Isochlorogenic acid A was shown to have hepatoprotec-
tive effects and antioxidative properties through the in-
duction of HO-1 [20]. Additionally, isochlorogenic acid
A has immunopotentiation properties mediated through
the NK-κB-induced release of NO from macrophages
[21]. Chlorogenic acid has been reported to inhibit the
production of inflammatory mediators and cytokines
[22,23]. Moreover, chlorogenic acid exhibits antibacter-
ial, antioxidant, anti-hepatic injury [24] and anti-allergic
activities [25].
We investigated the anti-inflammatory and anti-AD ef-
fects of AC treatment using in vitro and in vivo systems
because AD is strongly associated with the inflammatory
response. Treatment with AC suppressed both the pro-
duction of NO in LPS-stimulated RAW264.7 cells and
the production of histamine in PMA/A23187-stimulated
MC/9 mast cells. The involvement of Th2 cells both
helps to explain the joint involvement of IgE-producing
B cells (via IL-4 and IL-13), mast cells (via IL-4 and IL-
10) and eosinophils (via IL-5) in the allergic inflamma-
tory process and accounts for the other pathophysiologic
features of allergy [26]. Nc/Nga mice are characterized
by AD-like skin lesions and show elevated levels of
blood IgE [27]. The infiltration of mast cells is another
important factor in AD development. The dermatitis
scores were reduced following AC treatment at the third
week in D. farinae-sensitized Nc/Nga mice. In addition,
AC suppressed the histological features of the disease,
including edema, cornification of the epidermis, and
mast cell infiltration in the dorsal skin and ear. Further-
more, treatment with AC reduced the plasma levels of
histamine and IgE in D. farinae-sensitized Nc/Nga mice.
As a result, topical application of AC reduced inflamma-
tory response on destructive skin barrier functions,
which is caused by allergens, such as D. farinae, in AD
and thereby an increase of systemic IgE level was sup-
pressed. IgE induces mast cell activation, which results
in the release of preformed mediators, such as hista-
mine, and cytokines (IL-4 and IL-13). It is expected that
topical application of AC on the AD-like skin lesions re-
duces defective barrier functions by allergens and in-
hibits elevation of blood level of histamine via reduction
of activated mast cells by reduced systemic IgE.Conclusions
Our results suggest that AC reduces the atopic dermatitis
response of D. farinae-sensitized Nc/Nga mice via the in-
hibition of IgE-mediated mast cell degranulation. Add-
itionally, our data indicate that there is a reduction in the
release of preformed mediators, such as histamine. There-
fore, we conclude that AC should be explored as a poten-
tial therapeutic agent to treat atopic dermatitis.Competing interests
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